Back

Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation

1 September 2024 (14:47 - 15:00)
Organised by: Logo
Congress Presentation Part of: Registries, observational, and other studies on lipids Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Francois Schiele

Regional University Hospital Jean Minjoz, Besancon (France)

5 More presentations in this session

Presentation thumbnail
LDL-Cholesterol levels and lipid lowering therapy in secondary prevention patients: preliminary data from BRING-UP Prevention Study
Doctor A. Maggioni (Florence, IT)
Slides Video
Presentation thumbnail
Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London
Doctor M. Akhtar (London, GB)
Slides Video
Presentation thumbnail
Intensive, early and sustained lowering of atherogenic lipoproteins after myocardial infarction and long-term prognosis: a nationwide cohort study of myocardial infarction patients
Ms J. Schubert (Uppsala, SE)
Slides Video
Presentation thumbnail
Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes after myocardial infarction: data from the SWEDEHEART registry
Associate Professor M. Leosdottir (Malmo, SE)
Slides Video
Presentation thumbnail
A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
Registries, observational, and other studies on lipids
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 14:47 CET
You may be interested in
thumbnail
Congress Session
Registries, observational, and other studies on lipids
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy
thumbnail
Congress Session
Changing face of lipid-lowering therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources